Tocilizumab in the treatment of COVID-19-a meta-analysis.

ABSTRACT:

Background

Interleukin-6 inhibitors showed promising results in observational trials of patients with coronavirus disease 2019 (COVID-19).

Aim

To evaluate whether interleukin-6 inhibitor tocilizumab (TCZ) reduces mortality among hospitalized COVID-19 patients.

Design

A systematic review and meta-analysis.

Methods

Systematic review and meta-analysis of randomized controlled trials (RCTs) comparing TCZ vs. placebo/control, for treatment of adults with COVID-19. Primary outcome was 28-30 days all-cause mortality. Search was conducted up to 1 April 2021. Two independent reviewers screened citations, extracted data and assessed risk of bias. Relative risk (RR) with 95% confidence intervals (CI) were pooled. We performed subgroup analysis for patients with critical i

SUBMITTER: Avni T 

PROVIDER: S-EPMC8243364 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature